First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients-Reference-Cited by-同舟云学术

First‐in‐human study with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients

Published:2022-06-08 Issue:2 Volume:131 Page:114-128
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharma Tox

Author:

Anliker‐Ort Marion¹²^ORCID,Dingemanse Jasper¹^ORCID,Hsin Chih‐hsuan¹^ORCID,Richard Muriel¹^ORCID,Huehn Eva³,Sabattini Giancarlo³,van de Wetering Jeroen⁴,Kornberger Rüdiger⁵,van den Anker John²,Kaufmann Priska¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology Idorsia Pharmaceuticals Ltd Allschwil Switzerland

2. Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB) University of Basel Basel Switzerland

3. Department of Preclinical Drug Metabolism and Pharmacokinetics Idorsia Pharmaceuticals Ltd Allschwil Switzerland

4. PRA Health Sciences Groningen The Netherlands

5. Parexel International GmbH Berlin Germany

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13756